<DOC>
	<DOC>NCT00920816</DOC>
	<brief_summary>The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.</brief_summary>
	<brief_title>Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically documented metastatic renal cell cancer with a component of clear cell histology. Evidence of measurable disease. Patients with mRCC must have received no prior systemic firstline therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both. Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy. Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Axitinib in First &amp; Second Line Treatment of Patients With Metastatic Renal Cell Cancer</keyword>
</DOC>